Trial · NCT05740566
Outcomes19
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
1 to 19 of 19
Download this page as JSON| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| SECONDARY | Progression Free Survival (PFS) | Up to approximately 4 years | |||
| SECONDARY | Change From Baseline in Selected Functional Scales and Disease Symptom Items Included in the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30) | Up to approximately 4 years | |||
| SECONDARY | Change From Baseline in Selected Disease Symptoms Included in the European Organization for Research and Treatment of Lung Cancer Quality of Life Questionnaire (EORTC-QLQ-LC13) | Up to approximately 4 years | |||
| SECONDARY | Objective Response Rate (ORR) | Up to approximately 4 years | |||
| SECONDARY | Disease Control Rate (DCR) | Up to approximately 4 years | |||
| SECONDARY | Duration of Response (DOR) | Up to approximately 4 years | |||
| SECONDARY | PFS at Year 1 | 1 year | |||
| SECONDARY | OS at Year 1, 2 and 3 | 1 year, 2 years and 3 years | |||
| SECONDARY | Number of Participants With Anti-tarlatamab Antibodies | Up to approximately 4 years | |||
| SECONDARY | Trough Concentration (Ctrough) of Tarlatamab | Up to 1 year | |||
| SECONDARY | Number of Participants Who Experienced Anti-tarlatamab Antibodies | Up to 1 year | |||
| SECONDARY | Change From Baseline in Pain Severity as Measured by Brief Pain Inventory - Short Form (BPI-SF) | Up to approximately 4 years | |||
| SECONDARY | Change From Baseline in Symptom Severity as Measured by Patient Global Impression of Severity (PGIS) Questionnaire | Up to approximately 4 years | |||
| SECONDARY | Change From Baseline in Symptoms and Overall Status as Measured by Patient Reported Impression of Change (PGIC) Questionnaire | Up to approximately 4 years | |||
| SECONDARY | Summary Scores of Patient-perceived Health at Each Assessment Visit Using the Visual Analogue Scale (VAS) as Measured by the 5-Level EuroQol-5 Dimension (EQ-5D-5L) | Up to approximately 4 years | |||
| SECONDARY | Change From Baseline in Patient Perceived Health Using VAS Score as Measured by EQ5D-5L | Up to approximately 4 years | |||
| SECONDARY | Responses to Patient-Reported Adverse Events Questionnaire (PRO-CTCAE) | Up to approximately 4 years | |||
| SECONDARY | Change From Baseline in Symptom Bother as Measured by Functional Assessment of Cancer Therapy - General (FACT-G) Questionnaire | Up to approximately 4 years | |||
| PRIMARY | Overall Survival (OS) | From randomization up to minimum of death or primary completion DCO date 29 January 2025; median (min, max) time on the study was 8.6 (0.1, 18.5) months | The ITT analysis set included all randomized participants. | months | MEDIAN |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT05740566/outcomes